Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MGLL | Q99685 | 7/20 | 0.36 |
| ▸ | RORC | P51449 | 9/20 | 0.33 |
| ▸ | LMNA | P02545 | 1/20 | 0.31 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.31 |
| ▸ | HTT | P42858 | 1/20 | 0.31 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.31 |
| ▸ | DPP4 | P27487 | 1/20 | 0.31 |
| ▸ | PREP | P48147 | 1/20 | 0.31 |
| ▸ | DPP7 | Q9UHL4 | 1/20 | 0.31 |
| ▸ | F2R | P25116 | 1/20 | 0.30 |
| ▸ | SCD5 | Q86SK9 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL30700390 | 0.88 | GPBAR1 (0.36) | MGLLRORC | |
| SCHEMBL30700095 | 0.82 | MGLL (0.37) | MGLL | |
| SCHEMBL30700221 | 0.81 | MGLL (0.39) | MGLL | |
| SCHEMBL25327992 | 0.80 | MGLL (0.42) | MGLLRORCLMNAMAPK1HTT | |
| SCHEMBL25324952 | 0.80 | MGLL (0.42) | MGLLRORCLMNAMAPK1HTT | |
| SCHEMBL30700437 | 0.78 | MGLL (0.40) | MGLLRORCLMNAMAPK1HTT | |
| SCHEMBL30700835 | 0.77 | CACNA1B (0.38) | MGLL | |
| SCHEMBL30700254 | 0.77 | NAMPT (0.35) | MGLLHTTSMN1; SMN2 | |
| SCHEMBL30700475 | 0.76 | MGLL (0.38) | MGLLPREP | |
| SCHEMBL30700327 | 0.74 | GPR119 (0.34) | MGLLDPP4 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| WO-2023247670-A1 | NEW HETEROCYCLIC-CARBONYL-CYCLIC COMPOUNDS AS MAGL INHIBITORS | F. HOFFMANN-LA ROCHE AG (CH) | 2023-12-28 | — | — | WO | disclosed |